What is IMIBIC? - NHS Confederation/media/Confederation/Files/public access... · What is IMIBIC?...

What is IMIBIC?

IMIBIC is the Maimónides Institute for Biomedical Research of Córdoba

It is a Research Institute aimed at fostering a rich multidisciplinary

scientific environment in Biomedicine, where basic and clinical research

groups evolve together by developing interrelated scientific projects

aimed at solving health-related problems relevant for society.

The institute encourages and supports research groups towards

achievement of excellence in science, innovation, internationalization and

translational research.

Andalusian Regional Government’s Ministry of

Economy, Innovation, Science and Employment

Andalusian Regional Government’s

Ministry of Health and Social Welfare

University of Cordoba

Biomedical Research Foundation of

Cordoba: FIBICO

IMIBIC RESULTS FROM THE JOINT COLLABORATIVE EFFORT DEVELOPED BY DIFFERENT INSTITUTIONS

IMIBIC IS LOCATED WITHIN THE UNIVERSITY HEALTH SCIENCES CAMPUS BY THE REINA SOFIA UNIVERSITY HOSPITAL OF CÓRDOBA

September, 2013

Governing Board

5 Scientific Programs: Researchers Groups

Scientific Director

Scientific Vice-Director

GeneralManager

Administrative Management Unit and

Innovation and Research Transfer Office

Research Core FacilitiesAnimal Housing Unit

External Scientific Committee

FIBICO Foundation (Managerial support)

ScientificCouncil

INSTITUTIONAL STRUCTURE

Active ageing and

Frailty

Inmonology and Senesence

Care of Chronic Patients

Frailty and quality of life in

the elderly

Diet, Endocrine

and Metabolic diseases

Metabolic Syndrome

Reproductive Health

Paediatric and PerinatalDiseases

Neuroendocrinetumours

Infectious and

Immunological

diseases. Transplant

AIDS+ Virus C

Transplant

Multiple drug resistence

Cancer :

Oncology & Oncohematology

Lung Cancer

Breast Cancer

Hepatocarcinoma

Leukemias and Lymphomas

Digestive Cancer

Others Tumours

Chronic and Inflammatory

diseases

Cardiovascular Diseases

Musculoskeletal system and

Connective Tissue Diseases

Neurological Diseases

Mental Health

Kidney and Urologic Diseases

Liver and Digestive Diseases

Chronic inflammation and

Signalling diseases

SCIENTIFIC RESEARCH PROGRAMS AND SUBPROGRAMS

1. To guide the research activity toward the most relevant

Health Topics

2. To generate a tool to promote the cooperation around

the same target

3. To generate a scientific design able to improve the

interaction between groups with different (or similar)

research profiles of expertise.

SCIENTIFIC PROGRAMS Looking for a Different Approach

Research Core Facilities

Cytometry & Confocal Microscopy: 1 Technician (PhD)

Proteomics: 2Technicians (PhD)

Bioinformatics: 2Technicians (PhD)

Radioisotope Laboratory: 1 Technician

Animal Housing Unit: 3Technicians

Methodology & Biostatistics: 1 Technician (PhD)

Biobank: 4Technicians

Clinical Research Unit: 4 Technicians

Infrastructure: General lab equipment, animal unit equipment, mass

spectrometry, cell culture, confocal microscopy, Ephysiology, Isotope lab

THE SCIENTIFIC STRUCTURE

22

Consolidated Groups (CG)

2

Emergent Groups (EG)

8

Associated Groups (AG)

COD GROUPS RESEARCHERS

CG1

Immunosenescence T and NK. Antiviral Immune response Dr. Rafael Solana Lara (HR)

PROGRAMS 1, 3, 5Dr. José Peña Martínez (CO-HR)

CG2

Oxidative and Nitrosative Stress in Acute and Chronic Liver

DiseasesDr. Manuel De La Mata García (HR)

PROGRAMS 3, 4, 5 Dr. José Antonio Bárcena Ruiz (CO-HR)

CG3Infectious Diseases Dr. Julián De La Torre Cisneros (HR)

PROGRAMS 3, 5 Dr. Antonio Rivero Román (CO-HR)

CG4Inflammation and Cancer Dr. Eduardo Muñoz Blanco (HR)

PROGRAMS 2, 3, 4, 5 Dr. Marco Calzado (ER)

CG5

Systemic autoimmune and chronic inflammatory diseases

of the musculoskeletal system and connective tissueDr. Rosario López Pedrera (HR)

PROGRAMS 2, 5 Dr. Eduardo Collantes Estévez (CO-HR)

CG6

New Cancer Therapies Dr. Enrique Aranda Aguilar (HR)

PROGRAM 4Dr. Antonio Rodríguez Ariza (CO-HR)

Dr Juan de la Haba (ER)

CG7

Nephrology.

Cellular Damage in Chronic InflammationDr. Pedro Aljama García (HR)

PROGRAM 5 Dr. Julia Carracedo Añón (CO-HR)

CG8

Hormones and Cancer Dr. Justo P. Castaño Fuentes (HR)

PROGRAMS 2, 4 Dr. Francisco Gracia Navarro (CO-HR)

Dr. Raúl Luque González (CO-HR)

SCIENTIFIC PROGRAM: CONSOLIDATED

RESEARCHERS GROUPS


RESEARCHERS GROUPS


CG9Nutrigenomics and Metabolic Syndrome Dr. José López Miranda (HR)

PROGRAMS 1, 2, 4, 5 Dr. Francisco Pérez Jiménez (CO-HR)

CG10

Hormonal regulation of energy balance, puberty and

reproduction Dr. Manuel Tena Sempere (HR)

PROGRAMS 2, 4

CG11

Metabolism and Adipocyte Differentiation.

Metabolic SyndromeDr. Mª del Mar Malagón Poyato (HR)

PROGRAMS 2 Dr. Francisco Gracía Navarro (CO-HR)

CG12Epidemiological Research in Primary Care

Dr. Luis Ángel Pérula de Torres (HR)PROGRAMS 4, 5

CG13Calcium Metabolism. Vascular Calcification

Dr. Mariano Rodríguez Portillo (HR)

PROGRAMS 2, 5

CG14Cellular Therapy

Dr. I. Concepción Herrera Arroyo (HR)PROGRAM 5

CG15Invasive Cardiology and Cellular Therapy

Dr. José Suárez De Lezo Cruz-Conde (HR)PROGRAM 5

CG16Cellular Biology in Haematology. Hypercoagulability Dr. Joaquín Sánchez García (HR)

PROGRAM 4 Dr. Francisco Velasco Gimena (CO- HR)


RESEARCHERS GROUPS


CG17

Pathophysiology of endocrine vitamin D system

Biotechnology and aging Dr. José Manuel Quesada Gómez (HR)

PROGRAM 1, 2

CG18

Translational Research in Surgery of Solid Organs

Transplantation Dr. Javier Briceño Delgado (HR)

PROGRAM 4, 5

CG19Applications of Computer Vision

Dr. Rafael Medina Carnicer (HR)

PROGRAM 5

CG20Genetics and Behavioural Diseases

Dr. Manuel Ruiz Rubio (HR)

PROGRAM 5

CG21

Metabolomics.

Identification of Bioactive ComponentsDr. Mª Dolores Luque De Castro (HR)

PROGRAMS 2, 4, 5 Dr Feliciano Priego Capote (ER)

CG22

Epigenetics

Dr. Teresa Roldán Arjona (HR)

PROGRAM 4

SCIENTIFIC PROGRAM: EMERGING

RESEARCHERS GROUPS


EG1Oxidative Stress and Nutrition

Dr. Isaac Túnez Fiñana (ER)PROGRAMS 1, 2, 5

EG2Child Metabolism

Dr. Mercedes Gil Campos (ER)PROGRAM 2, 4


AG1Lung Transplants. Thoracic Neoplasms

Dr. Ángel Salvatierra Velázquez (AR)PROGRAM 4

AG2

Comprehensive Nursing Techniques.

Multi-disciplinary Perspectives Dr. Maria Aurora Rodríguez Borrego (AR)

PROGRAM 1, 5

AG3Pneumology

Dr. Bernabé Jurado Gámez (AR)PROGRAM 2, 5

AG4

Endocrinology and Nutrition. Insuline resistance,

Diabetes and MetabolismDr. Pedro Benito López (AR)

PROGRAM 2 Dr. Juan Antonio Paniagua González (ER)

AG5Study of Growth. Endocrinology and Child Nutrition

Dr. Ramón Cañete Estrada (AR)PROGRAM 2

AG6

Clinical Analysis Dr. Cristóbal Aguilera Gámiz (AR)

PROGRAM 2 Dr. Fernando Rodríguez Cantalejo (AR)

Dr. Javier Caballero Villarraso (AR)

AG7

Urology and Sexual Medicine Dr. Mª José Requena Tapia(AR)

PROGRAM 5 Dr. Francisco Anglada Curado (AR)

AG8Diagnostic imaging

Dr. Marina Álvarez Merino (AR)

SCIENTIFIC PROGRAM: ASSOCIATED

RESEARCHERS GROUPS

Staff

Head of research and Co-H 33

Researchers (R, AR, ER) 245

Post-doctoral Researcher 50

Trainee Researcher 85

Technician 34

Administrative assistant 6

Total Staff 453

THE SCIENTIFIC STRUCTURE

Q1 & Q2 PUBLICATIONSPUBLICATIONS (TOTAL + IF)

COLLABORATIONS

Scientific Activity

167 168 163219 253 281

614.63 640.71723.94

787.43

987.421080.45

0

200

400

600

800

1000

1200

2007 2008 2009 2010 2011 *2012

Nº PUBLICATIONS WITH FI IMPACT FACTOR

10087

106 109

147 152

3043 46

56 5466

0

20

40

60

80

100

120

140

160

2007 2008 2009 2010 2011 *2012

Quartil 1 Quartil 2

43%

39%

18%

Co -Nationals Groups

Co - International Groups

Intramural

CLINICAL TRIALS (Proactive strategy)

Activos Activos Activos Activos

2010 2011 2012 2013

4887

122 122

136

165

185229

EECC EEOO

Nuevos Nuevos Nuevos Nuevos

2010 2011 2012 2013

22

54 59 51

65

71 6660

EEOO EECC

EECC: Clinical TrialsEEOO: Observational Studies

Active

New

PATENTS

N. of Spin-off 2011-2013 5

Research Transfer (Activity & Patents)

0

2

4

6

8

10

12

14

16

2009 2010 2011 2012 2013

2

5

7

10

16

0 0 0

4 4

N. Patents

N. Licensed Patents

NHS – IMIBIC COLLABORATION

A GATEWAY TO THE ANDALUSIAN HEALTH SERVICE (SAS)

Why is the SAS (and IMIBIC) interested in the NHS? (and vice versa?)

Similar healthcare model (some features of our regional model are

inspired in the NHS)

Close relationship between basic and clinical researchers

Emphasis on translational medicine

Interest of SAS in specific areas (institutional collaboration):

E-Health / Telemedicine

Strategies for chronic diseases



What do IMIBIC and SAS look for in a research partner? Why the NHS?

World class facilities and professionals

At the forefront of biomedical research

Reliability and leadership

Numerous links already in place

Spanish researchers working in the UK or trained in the UK

How is our relationship with the NHS?

Primarily through direct contact (researchers)

Not yet materialised in a FP collaborative project (with IMIBIC)

What we would like…

Strengthen this relationship through the NHS European Office

Increase the number of new collaborations

Foster new projects (in H2020) from previous collaborations



Some examples of collaboration with the NHS and UK Universities:

Project Happi: Healthy Ageing – Public Procurement of Innovations

Funded by the EU CIP Programme

Coordinated by Resah-idf, with the participation of NHS Commercial Solutions and

IMIBIC-FIBICO

European Network of Paediatric Hodgkin’s Lymphoma

EPIDERM – European Prevention Initiative for Dermatological

Malignancies



Some examples of collaboration with the NHS and UK Universities

(Continue):

FLIP - Fatty Liver: Inhibition of Progression

DEVANI - Vaccine Against Neonatal Infections

SIMBASE – Promotion of ICT Enhanced Simulation Based Learning in

Healthcare Centers

LIPGEN - Diet, genomics and the metabolic syndrome: an integrated

nutrition, agro-food, social and economic analysis



Some examples IMIBIC researchers participation in EU FPs:

LIPGEN - Diet, genomics and the metabolic syndrome: an integrated

nutrition, agro-food, social and economic analysis

CANNABIS - Standardised extracts of Cannabis for use in the

treatment of migraine and rheumatoid arthritis

PK2-KISS - Physiological characterization of PK2 in the control of

fertility, and its interaction with kisspeptins

META-GNRH - Metabolic Targeting of GnRH Neurons: Molecular

Mechanisms and Neuropeptide Pathways

DEER - Developmental effects of environment on reproductive health



What are we doing now: CORDIOPREV (http://www.cordioprev.es/)

Interventional Study: > 1000 patients of Ischemic heart disease

Randomised comparative study: Two heart-healthy diets

Mediterranean vs. Low-fat diet

Already in 4th project-year

Follow-up of 5 years (median)



http://www.cordioprev.es/









What are we doing now (cont.):

MAGICBULLET (FP7) - Optimisation of treatment with off-patent

antimicrobial agents of ventilator-associated pneumonia (VAP)

(http://www.magicbullet7fp.eu/)

Coordinated by SAS: other partners from France, Italy, Greece,

Germany and Spain

COMBACTE (IMI) - Combating Bacterial Resistance in Europe

(http://www.imi.europa.eu/content/combacte)

Participation of SAS and NHS

http://www.magicbullet7fp.eu/









http://www.imi.europa.eu/content/combacte









What are we doing now (cont.):

PRECISEADS (IMI) - Molecular Reclassification to Find Clinically Useful

Biomarkers for Systemic Autoimmune Diseases

Coordinated by UCB and managed by SAS: other partners from

Portugal, Sweden, Belgium, Austria, Switzerland, Italy, France, Cyprus,

Hungary, Germany and Spain

Starts February 1st



Possible future collaborations (H2020):



IMIBIC Group Area Topic

CG1 Immune system and ageing

PHC 1 – 2014: Understanding health,

ageing and disease: determinants, risk

factors and pathways

CG7Effectiveness of different CKD therapies in

the elderly

PHC 17 – 2014: Comparing the

effectiveness of existing healthcare

interventions in the elderly

CG13 Phosphate intake and cardiovascular healthPHC 13 – 2014: New therapies for

chronic non-communicable diseases

CG14 Cellular therapyPHC 16 – 2015: Tools and technologies

for advanced therapies

EG2 Rare diseasesPHC 14 – 2015: New therapies for rare

diseases

AG2 Falls prevention

PHC 21 – 2015: Advancing active and

healthy ageing with ICT: Early risk

detection and intervention

Future collaborations already in place (with the NHS or other UK

institutions):

IMIBIC Group Area Topic

CG2 Liver transplant

PHC 10 – 2014: Development of new

diagnostic tools and technologies: in vitro

devices, assays and platforms

CG10 Endocrinology

PHC 1 – 2014: Understanding health, ageing

and disease: determinants, risk factors and

pathways.

MSCA-ITN

CG22 Epigenetic

PHC 10 – 2014: Development of new

diagnostic tools and technologies: in vitro

devices, assays and platforms

AG2 Elderly care COST 2014

FIBICO-IMIBIC Pre-Commercial Procurement Various topics





Possible future collaborations as partners (H2020):

Groups Topics

CG3, CG5, CG9, CG13 PHC1

CG3, CG13, CG20 PHC3

CG2 PHC10

CG2 PHC12

CG5, CG13, EG1, ORT PHC13

CG13 PHC15

CG16 PHC16

HURS PHC23

CG2 PHC24

CG9 PHC26

CG21 Several

José Carlos Prieto Baena │ Research Management Area

FIBICO - IMIBIC

Edificio Consultas Externas, Nivel -1

Hospital Universitario Reina Sofía

Avda. Menéndez Pidal s/n, 14004 Córdoba (Spain)

T (+34) 957 011 292

M (+34) 671 596 050

F (+34) 957 736 149

Thank you for your attention!

What is IMIBIC? - NHS Confederation/media/Confederation/Files/public access... · What is IMIBIC?...

Documents

Transcript of What is IMIBIC? - NHS Confederation/media/Confederation/Files/public access... · What is IMIBIC?...